Cuts will slow Japan's vascular access market
This article was originally published in Clinica
Japan's rapidly ageing population (by 2015, more than one-quarter of the nation will be considered "elderly") will lead to an increase in infusion therapies, such as vascular access (VA) procedures, to treat cancer and end-stage renal disease. So says a report by Canadian healthcare research firm, Millennium Research Group.
You may also be interested in...
The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.